Currently melanoma is the deadliest form of skin cancer and one of the most common cancers in women under 40 years old in the United States. The first line of defense in helping to reduce the risk of developing melanoma is by wearing broad spectrum UVA and UVB SPF protection. L’Oréal Paris, a leading global beauty brand, and Melanoma Research Alliance (MRA), the leading private funder of melanoma research, announced today the launch of It’s THAT Worth It To Me. This social media campaign encourages women to donate 15 social media seconds by sharing why SPF protection or using sunless tanner is worth it to protect their skin, their beauty and their life. For every social share, L’Oréal Paris will donate $1 to MRA to fund the L’Oréal Paris - MRA Team Science Award Research Grant, up to $250,000 in 2015.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7459051-l-oreal-paris-mra-it-s-that-worth-it/
Unlocking the Social Potential in Autism, by Dr. Karina Poirier, is an in-depth guide to understanding autism. It empowers parents to teach their children valuable skills essential for developing friendships and achieving academic success. www.socialcognitionpublications.com
Video production by Castelane.
If diagnosed early enough 90% of melanoma cases can be treated effectively. An exclusive study carried out by Ipsos for La Roche-Posay in 23 countries across all continents looks into the different attitudes to the sun and general knowledge of the risks associated with exposure. A massive 88% of those questioned are aware of the risks of developing skin cancer when exposed without protection to the sun. However, just 1 in 2 of those questioned have ever consulted a dermatologist for a mole screening and 1 in 4 of them have never even checked their own moles on their body.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7438251-la-roche-posay-become-skin-checker/
Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
Syneron Medical Ltd., the leading global aesthetic device company, announced to a group of international media its new activities and enhanced global commitment to developing the non-invasive body shaping market, one of the fastest growing segments in the global aesthetic medical device market. The press conference took place at the Academy of Medical Sciences in London, just prior to the opening of the BODY Conference and Exhibition, which took place in London on November 3-4, 2012 and for which Syneron was the main sponsor.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58631-body-shaping-by-syneron
Global demand for food has never been higher, as populations skyrocket and developing areas of the world strive to feed their citizens. But in the United States, more than one–third of the food produced is never eaten and a new online survey of U.S. grocery shoppers’ attitudes conducted by Harris Poll on behalf of Sealed Air Corporation (NYSE: SEE) shows that food waste in the U.S. is near the top of the list of consumers’ environmental concerns and they are willing to change behaviors if better informed on the issue. The April 2014 study interviewed over 1,000 U.S. adults (aged 18+) who do at least 25% of their household’s grocery shopping (“American grocery shoppers”).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7270651-sealed-air-2014-food-waste-survey/
With 830 women dying every day from preventable causes related to pregnancy and childbirth, and over 16,000 children under age five dying daily, Bayer and the White Ribbon Alliance today released critical policy recommendations and launched community programs to support the reduction and prevention of maternal, newborn and child mortality in two developing countries.1,2
Established through a three-year $1.3 million commitment from Bayer, these programs will expand work conducted by White Ribbon Alliance in Bangladesh and Zimbabwe to support the United Nations Secretary General’s Every Woman Every Child movement.
This announcement comes at the one-year anniversary of the Bayer/White Ribbon Alliance commitment in support of the Every Woman Every Child movement and will contribute to the success of the Sustainable Development Goals.
To view the multimedia release go to:
http://www.multivu.com/players/English/77126510-bayer-white-ribbon-alliance-self-care/
The Investor Desk Presents US Highland, Inc. (OTC PINK: UHLN), a diversified product development, sales, and marketing company.
Since its founding in 1997 as Highland AB in Sweden, the Texas-based company has been developing and manufacturing high-performance single cylinder and V-twin powertrains used for a variety of applications. In September 2015, the publicly traded company began diversifying its operations, guiding startups in the marketing, reselling, and distributing of their products, as well as helping customers establish their brand and penetrate the U.S. market.
Overseeing the company’s growth is chief executive officer and president Josh Whitaker, a marketing executive with global experience in technology marketing, strategy, and implementation. Whitaker has worked with high-profile brands like Red Bull and Under Armour, as well as industry leading companies like Tucker Rocky Distributing and KTM Motorcycles.
Over the past two decades, US Highland, Inc. has tapped a variety of distribution channels, enabling growing businesses, both domestic and foreign, to launch their products in the United States whether wholesale, retail, or over the Internet.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7660851-us-highland-the-investor-desks-new-company/
Miral and SeaWorld Entertainment, Inc. (NYSE:SEAS) (“SeaWorld”) today announced their partnership to develop SeaWorld Abu Dhabi, a first-of-its-kind marine life themed park on Yas Island. This next generation SeaWorld Abu Dhabi will also include the United Arab Emirates’ (“UAE”) first dedicated marine life research, rescue, rehabilitation and return center with world-class facilities and resources for the care and conservation of local marine life. SeaWorld Abu Dhabi will be the first new SeaWorld without orcas, and will integrate up-close animal experiences, mega attractions and a world class aquarium, bringing the latest technology in visitor engagement.
The partnership brings together Miral’s expertise in developing Yas Island’s portfolio of destinations with SeaWorld’s 50-plus years of theme park, veterinary medicine, marine science and zoological practice and experience.
To view the multimedia release go to:
http://www.multivu.com/players/uk/8002251-miral-announces-seaworld-yas-island/
Stella Artois, part of the Anheuser-Busch family of brands, and Water.org today announced a call to action for all beer lovers who plan to watch this year’s Super Bowl, the most highly watched event of the year. By stocking up on Stella Artois beer for the big game and beyond, people across the country can help provide access to clean water for those in the developing world. More than 663 million people are impacted by the global water crisis today.
From January 15 until April 15 of this year, every purchase of a Stella Artois 12-pack (both bottles and cans, including Stella Artois Cidre) will help Water.org provide 12 months of clean water for one person in the developing world. For those watching the big game at a bar, the purchase of one pint or bottle of Stella Artois will help provide one month of clean water. And as in years past, in 2018 every purchase of a Limited-Edition Stella Artois Chalice will help provide five years of clean water for one person in the developing world.
To view the multimedia release go to:
https://www.multivu.com/players/English/8254751-stella-artois-water-org-super-bowl-party/
Vestergaard, a global company dedicated to improving the health of disadvantaged people, launched its LifeStraw® Follow the Liters program in Kenya this month. As part of this program, high-volume LifeStraw® Community water purifiers have been distributed to provide more than 23 million liters of safe water a year to over 125,000 school children throughout Kenya’s western province.
The distribution is made possible through the LifeStraw® Follow the Liters program which harnesses the collective power of individuals to help solve one of the world’s most pressing issues – lack of access to safe drinking water for people in developing countries. When a consumer purchases any LifeStraw® product, a portion of the funds are used to provide one school child in a developing country with safe drinking water for an entire school year.
To view the Multimedia News Release, go http://www.multivu.com/players/English/7351651-vestergaard-lifestraw-follow-the-liters-program-kenya-safe-water/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
